sellModerate cluster of 310b5-1 plan
Stacy Ann Coen sold $1.7M of IMGN
SVP & CHIEF BUSINESS OFFICER at ImmunoGen, Inc.. 108,609 shares at an average of $16.04, traded Nov 15, 2023, filed Nov 17, 2023.
Warning score
40Value
$1.7M
108,609 shares
Holdings after
36,966
-172% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$1.7M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-23-015268, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2023 | MOption exercise Common Stock10b5-1 | +20,986 | $4.92 | $103k | 57,952 | Nov 17, 2023 |
| Nov 15, 2023 | MOption exercise Common Stock10b5-1 | +5,300 | $7.69 | $41k | 63,252 | Nov 17, 2023 |
| Nov 15, 2023 | SOpen-market sale Common Stock10b5-1 | -26,286 | $16.01 | $421k | 36,966 | Nov 17, 2023 |
| Nov 16, 2023 | MOption exercise Common Stock10b5-1 | +3,200 | $4.92 | $16k | 40,166 | Nov 17, 2023 |
| Nov 16, 2023 | MOption exercise Common Stock10b5-1 | +900 | $7.69 | $6,921 | 41,066 | Nov 17, 2023 |
| Nov 16, 2023 | SOpen-market sale Common Stock10b5-1 | -4,100 | $16.01 | $66k | 36,966 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Common Stock10b5-1 | +2,200 | $4.92 | $11k | 39,166 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Common Stock10b5-1 | +76,023 | $7.69 | $585k | 115,189 | Nov 17, 2023 |
| Nov 17, 2023 | SOpen-market sale Common Stock10b5-1 | -78,223 | $16.05 | $1.3M | 36,966 | Nov 17, 2023 |
| Nov 15, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,986 | $0.00 | $0 | 54,223 | Nov 17, 2023 |
| Nov 15, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 153,710 | Nov 17, 2023 |
| Nov 16, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,200 | $0.00 | $0 | 51,023 | Nov 17, 2023 |
| Nov 16, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -900 | $0.00 | $0 | 152,810 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,200 | $0.00 | $0 | 48,823 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -76,023 | $0.00 | $0 | 76,787 | Nov 17, 2023 |
Related signals
Other insiders at ImmunoGen, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | ImmunoGen, Inc. | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | $134k 4,583 shares | -6% | |
| 24Weak | ImmunoGen, Inc. | Mark J Enyedy CHIEF EXECUTIVE OFFICER | $589k 20,107 shares | -3% | |
| 8Weak | ImmunoGen, Inc. | Renee Lentini VP & PRIN ACCTG OFFICER | $77k 2,631 shares | -15% | |
| 20Weak | ImmunoGen, Inc. | Theresa Wingrove SVP OF REGULATORY AFFAIRS | $352k 12,027 shares | -36% | |
| 25Weak | ImmunoGen, Inc. | Theresa Wingrove SVP OF REGULATORY AFFAIRS | $5.6M 187,667 shares | -98% | |
| 10Weak | ImmunoGen, Inc. | Renee Lentini VP & PRIN ACCTG OFFICER | $195k 6,548 shares | -44% | |
| 33Weak | ImmunoGen, Inc. | Theresa Wingrove SVP OF REGULATORY AFFAIRS | $3.5M 117,445 shares | -98% | |
| 25Weak | ImmunoGen, Inc. | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | $112k 3,826 shares | -10% | |
| 34Weak | ImmunoGen, Inc. | Kristine Peterson director | $578k 20,000 shares | -100% | |
| 40Moderate | ImmunoGen, Inc. | Theresa Wingrove SVP OF REGULATORY AFFAIRS | $4.9M 171,216 shares | -1783% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.